The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 21, 2023

Filed:

Oct. 31, 2018
Applicant:

Pantarhei Bioscience B.v., Zeist, NL;

Inventors:
Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 38/17 (2006.01); A61P 35/00 (2006.01); A61P 35/04 (2006.01); A61K 39/39 (2006.01); A61K 35/15 (2015.01); A61K 38/08 (2019.01); C07K 14/705 (2006.01); A61K 47/68 (2017.01); A61K 35/17 (2015.01); A61K 39/395 (2006.01); A61K 51/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/001114 (2018.08); A61K 35/15 (2013.01); A61K 38/08 (2013.01); A61K 38/177 (2013.01); A61K 38/1774 (2013.01); A61K 39/001111 (2018.08); A61K 39/39 (2013.01); A61P 35/00 (2018.01); A61P 35/04 (2018.01); A61K 35/17 (2013.01); A61K 39/3955 (2013.01); A61K 47/68 (2017.08); A61K 51/00 (2013.01); A61K 2039/5154 (2013.01); A61K 2039/5158 (2013.01); A61K 2039/53 (2013.01); C07K 14/705 (2013.01); C07K 14/70503 (2013.01);
Abstract

The present invention relates to treatment and diagnosis of lung cancer and metastases thereof. More specifically, the invention relates to such therapeutic use of antigen sources providing immunogenic polypeptides comprising at least an immunogenic portion of a cancer cell associated protein, which preferably is a zona pellucida (ZP) protein, especially a ZP3 protein or the extracellular domain thereof, whereby the antigen source induces a cellular immune response against the lung cancer cells. The antigen source can be a proteinaceous composition comprising such immunogenic ZP polypeptide, a nucleic acid encoding the immunogenic ZP polypeptide, or a cell expressing or presenting the immunogenic ZP polypeptide. In addition, the invention relates to the therapeutic use of a T cell comprising a T cell receptor that binds an MHC-peptide complex, wherein the peptide is a peptide from the immunogenic ZP polypeptide. The invention further relates to the therapeutic and/or diagnostic use of antibodies that specifically binds to the immunogenic ZP polypeptide.


Find Patent Forward Citations

Loading…